Neumora Therapeutics, Inc. Common Stock (NMRA) vs PolyPid Ltd. (PYPD)
A side-by-side comparison of Neumora Therapeutics, Inc. Common Stock and PolyPid Ltd. across valuation, profitability, dividends, and growth — built entirely from reported fundamentals, as of October 6, 2026. Differences are shown without an overall score or investment verdict.
NMRA
Neumora Therapeutics, Inc. Common Stock
$0.48HealthcareDelayed quote: Oct 6, 2026, 12:25 PM EDT
PYPD
PolyPid Ltd.
$5.17HealthcareDelayed quote: Oct 6, 2026, 12:14 PM EDT
Total return — NMRA vs PYPD
growth of $100 · dividends reinvested · last 3yNMRA -96.8% (-68.1%/yr)PYPD -26.2% (-9.6%/yr)PYPD compounded faster over this window
Log scale — wide-divergence pair
NMRA PYPD
NMRA vs PYPD: by the numbers
- •PYPD is the larger company ($99M vs $90M market cap).
Metrics side by side
Valuation
| Metric | NMRA | PYPD |
|---|---|---|
| P/B ratio | 2.01 | 18.29 |
Profitability
| Metric | NMRA | PYPD |
|---|---|---|
| Gross margin | 0.00% | 0.00% |
| Operating margin | 0.00% | 0.00% |
| Net margin | 0.00% | 0.00% |
| ROE | -477.87% | -584.65% |
| ROIC | -216.05% | 13.49% |
Growth (annualized)
| Metric | NMRA | PYPD |
|---|---|---|
| Total return CAGR (5Y) | N/A | -52.69% |
Go deeper
Dig into the metrics
Figures are sourced from reported fundamentals and the latest end-of-day price. This comparison is informational only and is not investment advice. Past performance does not predict future results. See our methodology. Compiled by TGMCharts Research · data verified October 6, 2026.